vic3308

º²É­ÖÆÒ© º²É­ÖÆÒ©

ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾ ¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • vic3308¥Y
ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾
ÐÂÎÅÐû²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅÐû²¼
2023 WCLC | º²É­ÖÆÒ©°¢ÃÀÌæÄáЯ42ƪÁ¢ÒìЧ¹ûÔٵǹú¼ÊѧÊõÎę̀
Ðû²¼ÈÕÆÚ£º2023/08/08
×ÖºÅ

Óɹú¼Ê·Î°©Ñо¿Ð­»á(IASLC)Ö÷ÀíµÄ2023ÌìÏ·ΰ©´ó»á(WCLC)¼´½«ÓÚ9ÔÂ9ÈÕÖÁ12ÈÕÔÚÐÂ¼ÓÆÂ¾ÙÐС£¡£ ¡£¡£ ¡£±¾½ì´ó»á½«½ÒÏþº²É­ÖÆÒ©¼×»ÇËá°¢ÃÀÌæÄáÆ¬42ƪÁ¢ÒìЧ¹û£¬£¬£¬£¬£¬£¬£¬£¬ÌåÏÖÁ˹ú¼ÊÖ×Áöѧ½ç¶ÔÖйúÔ­ÑÐÁ¢ÒìµÄ¸ß¶ÈÈϿɡ£¡£ ¡£¡£ ¡£


WCLCÊÇÌìÏÂÉϹæÄ£×î´óµÄÒԷΰ©ÎªÖ÷ÌâµÄ¶àѧ¿ÆÖ×ÁöѧÊõ¾Û»á£¬£¬£¬£¬£¬£¬£¬£¬Àú½ì¾ùÓжàÏîÖØ°õÁÙ´²Ñо¿Ð§¹ûÔÚ´ËÐû²¼²¢Ö¸µ¼ËæºóµÄÁÙ´²Êµ¼ù¸üУ¬£¬£¬£¬£¬£¬£¬£¬¿°³ÆÈ«Çò·Î°©ÁìÓòÑо¿Ï£Íû¡°·çÏò±ê¡±¡£¡£ ¡£¡£ ¡£


×÷Ϊº²É­ÖÆÒ©×ÔÖ÷Ñз¢µÄÖйúÊ׸öÔ­´´Èý´úEGFR-TKI£¬£¬£¬£¬£¬£¬£¬£¬°¢ÃÀÌæÄáÒÀ¸½×¿Ô½µÄÁÆÐ§ºÍÇå¾²ÐÔÓÅÊÆ£¬£¬£¬£¬£¬£¬£¬£¬ÔøÒ»ÔÙ»ñµÃ¹ú¼ÊȨÍþÈϿɣ¬£¬£¬£¬£¬£¬£¬£¬ÔÚSCIÆÚ¿¯»ò¹ú¼Ê´ó»áÉϽÒÏþµÄÏà¹ØÐ§¹û¾ÍÒÑÁè¼Ý100ƪ¡£¡£ ¡£¡£ ¡£Îª½øÒ»²½¾ò¿Í°¢ÃÀÌæÄáÔڷΰ©Ï¸·ÖÁìÓòµÄÖÎÁÆÇ±Á¦£¬£¬£¬£¬£¬£¬£¬£¬»Ý¼°¸ü¶à·ÇСϸ°û·Î°©(NSCLC)»¼Õߣ¬£¬£¬£¬£¬£¬£¬£¬Õë¶Ô¸ü¶à˳Ӧ֢µÄÁÙ´²ÊÔÑéÕýÔÚ¼ÓËÙÍÆ½øÖУ¬£¬£¬£¬£¬£¬£¬£¬°üÀ¨°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÃô¸ÐÍ»±äNSCLC¡¢ÍŽẬ²¬Ë«Ò©»¯ÁÆÒ»ÏßÖÎÁÆEGFRÃô¸ÐÍ»±äNSCLCµÈ¶à¸öÁÙ´²Ñо¿£¬£¬£¬£¬£¬£¬£¬£¬ÒÔÆÚΪ¸ü¶àNSCLC»¼ÕßÌṩ´ÓÔçÆÚµ½ÍíÆÚ£¬£¬£¬£¬£¬£¬£¬£¬´ÓΧÊÖÊõÆÚ¸¨ÖúÖÎÁƵ½Ò»Ïß¼°ºóÏßÖÎÁƵÄÈ«·½Î»¶àά¶ÈµÄÓÃÒ©¼Æ»®¡£¡£ ¡£¡£ ¡£


±¾½ìWCLCÉÏ£¬£¬£¬£¬£¬£¬£¬£¬°¢ÃÀÌæÄá½ÒÏþµÄ42ƪЧ¹û°üÀ¨3ƪ¿ÚÍ·±¨¸æ(Ñо¿Êý¾Ý)¡¢18ƪͨÀýÕªÒª(Ñо¿Êý¾Ý)¡¢13ƪ²¡Àý±¨µÀºÍ8ƪÑо¿Éè¼Æ£¬£¬£¬£¬£¬£¬£¬£¬½«Õ¹Ê¾°¢ÃÀÌæÄáÔÚNSCLC°ÐÏòÍŽáÖÎÁÆ¡¢ÄÔ(Ĥ)×ªÒÆ¡¢Ð¸¨Öú¡¢Ï¸·ÖÈËȺ¡¢Çå¾²ÐÔ¡¢ÉúÑÄÖÊÁ¿µÈÆ«ÏòµÄ×îÐÂÑо¿Ï£Íû¡£¡£ ¡£¡£ ¡£


¿ÚÍ·±¨¸æ£º3ƪ

1.Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study

°¢ÃÀÌæÄáÍŽᰲÂÞÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±ä°éÄÔ×ªÒÆ»¼ÕßµÄÓÐÓÃÐÔ¼°Çå¾²ÐÔ£ºµ¥±ÛIIÆÚÑо¿

ÈëÑ¡ÐÎʽ£ºOral£¬£¬£¬£¬£¬£¬£¬£¬±àºÅ£ºOA03.03

ͨѶ×÷ÕߣºÖÐɽ´óѧÖ×Áö·ÀÖÎÖÐÐÄ£¬£¬£¬£¬£¬£¬£¬£¬³ÂÀöÀ¥

µÚÒ»×÷ÕߣºÖÐɽ´óѧÖ×Áö·ÀÖÎÖÐÐÄ£¬£¬£¬£¬£¬£¬£¬£¬³Â¾²

±¨¸æÊ±¼ä£º±±¾©Ê±¼ä2023Äê9ÔÂ10ÈÕ12:32-12:42

 

2.Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study

°¢ÃÀÌæÄáÍŽᰠ£¿£¿£¿£¿£¿ËÌæÄáÓÃÓÚ°éÖÐÊàÉñ¾­ÏµÍ³×ªÒƵÄEGFRÍ»±äNSCLCÒ»ÏßÖÎÁÆ£ºÒ»ÏîǰհÐÔ¢ñ/¢òÆÚÑо¿

ÈëÑ¡ÐÎʽ£ºMini Oral£¬£¬£¬£¬£¬£¬£¬£¬±àºÅ£ºMA13.05

ͨѶ×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬»ÆÃľê

µÚÒ»×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÓàÃô

±¨¸æÊ±¼ä£º±±¾©Ê±¼ä2023Äê9ÔÂ11ÈÕ15:57-16:02

 

3.Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS)

°¢ÃÀÌæÄáÍŽᰲÂÞÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äÐÍ·ÇСϸ°û·Î°©£ºIIÆÚÑо¿(ALWAYS)

ÈëÑ¡ÐÎʽ£ºWorkshop/Oral£¬£¬£¬£¬£¬£¬£¬£¬±àºÅ£ºWS02.12/P2.09-32

µÚÒ»×÷Õß £º¹ã¶«Ò½¿Æ´óѧÁ¥ÊôÒ½Ôº£¨Õ¿½­£©£¬£¬£¬£¬£¬£¬£¬£¬³Â»ªÁÖ

±¨¸æÊ±¼ä£º±±¾©Ê±¼ä2023Äê9ÔÂ9ÈÕ10:40-10:50


Ñо¿Êý¾Ý£º18ƪ

1.Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer

°¢ÃÀÌæÄá¶þÏß»òÈýÏßÖÎÁÆT790MÒõÐÔ/δ֪·ÇСϸ°û·Î°©»¼ÕßµÄÓÐÓÃÐÔºÍÇå¾²ÐÔ

ÈëÑ¡ÐÎʽ£ºPoster£¬£¬£¬£¬£¬£¬£¬£¬±àºÅ£ºP2.09-06

×÷Õߣº±±¾©Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½½¡

 

2.Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated

°¢ÃÀÌæÄá¶ÔÍíÆÚEGFRÓÐÊýÍ»±ä·ÇСϸ°û·Î°©»¼ÕßµÄÇå¾²ÐÔºÍÓÐÓÃÐÔÑо¿£ºÐÐÁÐ2Êý¾Ý¸üÐÂ

ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-07

×÷ÕߣºÖÐɽ´óѧÁ¥ÊôÖ×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½ÎÄ·å

 

3.Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression

°¢ÃÀÌæÄá¼ÓÁ¿ÔÙÌôÕ½ÖÎÁÆ»ºÂýÏ£ÍûµÄÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßµÄÑо¿

ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-19

×÷Õߣº¼ªÁÖ´óѧÖÐÈÕÁªÒêÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Àî¾ü

 

4.Efficacy of Aumolertinib in EGFR T790M-negative or -unknown NSCLC with Brain Metastases Following Resistance to Prior EGFR-TKIs

°¢ÃÀÌæÄáÖÎÁÆÇ°ÏßEGFR-TKIsÄÍÒ©µÄEGFRT790MÒõÐÔ»òδ֪°éÄÔ×ªÒÆµÄNSCLC»¼ÕßµÄÁÆÐ§

ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-22

×÷ÕߣºÖйúÒ½¿Æ´óѧÁ¥ÊôÊ¢¾©Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬º«¬b²¨

 

5.Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions

°¢ÃÀÌæÄḨÖúÖÎÁƶÔÇгýµÄEGFRÍ»±äµÄ·ÇСϸ°û·Î°©ÒÔ¼°Ê£ÓàGGO²¡ÔîµÄÓ°Ïì

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP07.05-05

×÷ÕߣºËÕÖÝ´óѧÁ¥ÊôµÚÒ»Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Âíº£ÌÎ

 

6.HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIA EGFR Mutant Non-Small Cell Lung Cancer

IB-IIIAÆÚEGFRÍ»±äNSCLC»¼Õß°¢ÃÀÌæÄáÊõºó¸¨ÖúÖÎÁƵÄÉúÑÄÖÊÁ¿Ñо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP07.05-14

×÷ÕߣºÎ人´óѧÖÐÄÏÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ºúÎÀ¶«

 

7.Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial

°¢ÃÀÌæÄáи¨ÖúÖÎÁÆEGFRÍ»±äµÄ·ÇСϸ°û·Î°©£ºPURPOSEÊÔÑéµÄÑÇÐÐÁÐÆÊÎö

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP07.05-17

×÷ÕߣºÉϺ£ÊÐÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½ÎÄÌÎ

 

8.The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study

°ÂÏ£ÌæÄáÇå¾²ÐÔ²»ÄÍÊÜת°¢ÃÀÌæÄáÖÎÁƵÄEGFRÑôÐÔÍ»±ä·ÇСϸ°û·Î°©»¼ÕßµÄÇå¾²ÐÔºÍÓÐÓÃÐÔ»ØÊ×ÐÔÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-01

×÷ÕߣºÄϲý´óѧµÚÒ»Á¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ËïÁú»ª

 

9.The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment

ÍíÆÚNSCLC»¼Õß·þÓðÂÏ£ÌæÄáÄÍÊÜÐÔ²»¼Ñת»»°¢ÃÀÌæÄáµÄÇå¾²ÐÔºÍÓÐÓÃÐÔÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-16

×÷ÕߣºáéÖÝÊÐÈËÃñÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Ö£ÇÚºì

 

10.Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib

°¢ÃÀÌæÄáÀÖ³ÉÖÎÁÆÒò°ÂÏ£ÌæÄáÒýÆð¼äÖÊÐÔ·ÎÑ×EGFRÍ»±äµÄ·ÇСϸ°û·Î°©»¼ÕßµÄÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-19

×÷ÕߣºÕã½­´óѧҽѧԺÁ¥ÊôÉÛÒÝ·òÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬³Â¶÷¹ú

 

11.Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results

°¢ÃÀÌæÄáÒ»ÏßÖÎÁƾֲ¿ÍíÆÚ»ò×ªÒÆÐÔEGFR¹²Í»±ä·ÇСϸ°û·Î°©£ºÒ»Ïî»ØÊ×ÐÔÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-25

×÷ÕߣºÄϾ©ÊÐÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½Éê´æ

 

12.Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations

°¢ÃÀÌæÄáи¨ÖúºÍ¸¨ÖúÖÎÁÆIIIA-IVAÆÚ²»¿ÉÇгýµÄEGFRÍ»±ä·ÇСϸ°û·Î°©Ñо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-26

×÷ÕߣºÄϾ©ÊÐÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½Éê´æ

 

13.Real-World Outcomes of Health-Related Quality-of-Life (HRQoL) In Advanced Non-small Cell Lung Cancer Patients Treated with Aumolertinib

°¢ÃÀÌæÄáÖÎÁÆÍíÆÚ·ÇСϸ°û·Î°©»¼Õß¿µ½¡Ïà¹ØÉúÑÄÖÊÁ¿(HRQoL)µÄÕæÊµÌìÏÂЧ¹û

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-45

×÷ÕߣºÉ½¶«´óѧÆë³ҽԺ£¬£¬£¬£¬£¬£¬£¬£¬Àî¼ÊÊ¢

 

14.Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases

°¢ÃÀÌæÄáµ¥Ò©»òÍŽáÖÎÁÆÓÐÖ¢×´EGFRÍ»±äµÄ·ÇСϸ°û·Î°©ÄÔ×ªÒÆ»¼ÕßµÄÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-48

×÷ÕߣººÓÄÏÊ¡Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Íõ»Û¾ê

 

15.Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±ä·ÎÏÙÁÛ°©£ºÒ»Ïî¶àÖÐÐÄ¡¢µ¥±Û¡¢Ç°Õ°ÐÔÑо¿£¨ARISE£©

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-55

×÷Õߣº¸£½¨Ê¡Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÁÖ¸ù/»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ñÒÙ»

 

16.Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study

°ÂÏ£ÌæÄáÖÎÁƺóÇå¾²ÐÔ²»ÄÍÊܵÄEGFRÍ»±ä·ÇСϸ°û·Î°©»¼ÕßתΪ°¢ÃÀÌæÄáµÄ»ØÊ×ÐÔÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-63

×÷ÕߣºÍ­ÈÊÊÐÈËÃñÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Ò¦±ë

 

17.Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure

°¢ÃÀÌæÄáÍÅ½á¼Æ»®ÖÎÁƾ­°ÂÏ£ÌæÄáÖÎÁÆÊ§°ÜµÄÄÑÖÎÐÔÄÔÄ¤×ªÒÆEGFRÍ»±ä·ÇСϸ°û·Î°©»¼Õß

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-71

×÷ÕߣºÄϾ©ÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½Éê´æ

 

18.Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äµÄÍíÄê·ÇСϸ°û·Î°©»¼ÕßµÄÕæÊµÌìÏÂÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-72

×÷ÕߣºÄϾ©ÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½Éê´æ

 

²¡Àý±¨µÀ£º13ƪ

1.First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆÔ­·¢ÐÔEGFR T790MÍ»±äµÄ·ÇСϸ°û·Î°©(NSCLC)£º2Àý²¡Àý±¨µÀ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-14

×÷ÕߣºÌì½òÒ½¿Æ´óѧµÚ¶þÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ê°Á¢

 

2.Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report

°¢ÃÀÌæÄáÍŽáSBRTÖÎÁÆEGFR¹²Í»±äÓÐÖ¢×´ÄÔ×ªÒÆ»¼Õߣº²¡Àý±¨µÀ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-15

×÷ÕߣººÓÄÏÊ¡Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÕÅÏþ¾ê

 

3.A Case of Brain Metastases from Lung Cancer with Epilepsy and ECOG Score of 4 Successfully Treated with Aumolertinib

Ò»Àý°¢ÃÀÌæÄáÀÖ³ÉÖÎÁÆ·ÇСϸ°û·Î°©ÄÔ×ªÒÆ°éñ²ðïºÏ²¢PSÆÀ·Ö4·Ö»¼ÕߵIJ¡Àý±¨¸æ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-21

×÷ÕߣºÇ廪´óѧÁ¥Êô±±¾©Ç廪³¤¸ýÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÕÔ¾°È«

 

4.High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom

¸ß¼ÁÁ¿°¢ÃÀÌæÄáÍŽáÇÊÄÚ»¯ÁÆÖÎÁÆÒÔÄÔĤ֢״ΪÊ×·¢Ö¢×´µÄEGFRÍ»±äNSCLC»¼Õß

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-24

×÷ÕߣºÖØÇì´óѧÁ¥ÊôÈýϿҽԺ£¬£¬£¬£¬£¬£¬£¬£¬Íõΰ

 

5.A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis

°¢ÃÀÌæÄáÖÎÁÆÍíÆÚNSCLC°éÓаüÀ¨ÄÔ×ªÒÆÔÚÄڵĶ෢ÐÔ×ªÒÆ°©»¼Õß»ñµÃÓÀÉúÑĵIJ¡Àý±¨µÀ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-28

×÷Õߣº´óÁ¬Ò½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬µ¥Ðã

 

6.Intracranial Complete Remissions and Long-Term Response in a EGFR positive NSCLC Patient with Brain Metastases: Case Report

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±ä°é¶à·¢ÄÔ×ªÒÆNSCLC»¼Õß­ÄÚÍêÈ«»º½â²¢ÓÀÉúÑĵIJ¡Àý±¨µÀ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-32

×÷Õߣº¹ãÖÝÊз¬Ø®ÖÐÐÄÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ËÕºÆÈ»

 

7.Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations

°¢ÃÀÌæÄá¶ÔÓÐÊýµÄEGFR Exon20 V774MºÍS768IÍ»±äµÄÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßÓÐÓÃ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-37

×÷Õߣº°ö²ºÒ½Ñ§ÔºµÚÒ»Á¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÌÕÌÎ

 

8.Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib

°¢ÃÀÌæÄáÖÎÁÆÒ»ÀýMET 14ÍâÏÔ×ÓÌøÍ»ºÏ²¢EGFR 21 L858R¹²Í»±äµÄ·ÎÏÙ°©²¡Àý±¨¸æ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-44

×÷Õߣº¿Õ¾ü¾üÒ½´óѧÎ÷¾©Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ ³ÂÑÜ

 

9.Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases

¸ß¼ÁÁ¿°¢ÃÀÌæÄáÀÖ³ÉÕü¾È°éÄÔ¡¢ÄÔÄ¤×ªÒÆµÄT790MÒõÐÔEGFRÍ»±ä·ÇСϸ°û»¼Õß

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-56

×÷ÕߣºÏÃÃÅ´óѧÁ¥ÊôµÚÒ»Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÀîÒã±ó

 

10.Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report

²»¿ÉÇгýµÄ·ÇСϸ°û·Î°©»¼Õßͨ¹ý°¢ÃÀÌæÄáи¨ÖúÖÎÁÆ×ª»¯Îª¿ÉÇгý£º²¡Àý±¨µÀ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-57

×÷Õߣº×ñÒåÒ½¿Æ´óѧÁ¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬³Â³É

 

11.Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment

°¢ÃÀÌæÄáÍŽá·ÅÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔ×ªÒÆºÍÖØ´ó·Î²¿²¡ÔîµÄ»¼ÕßÒ»Á¬ÐÔÍêÈ«»º½â

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-58

×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÎâÇ¿

 

12.Long Survival in LM NSCLC Treated with Aumolertinib and Metronomic Intrathecal Pemetrexed under Dynamic Detection of CSF ctDNA

CSF ctDNA¶¯Ì¬¼à²âϰ¢ÃÀÌæÄáÍŽá½Ú×àʽÇÊÄÚ×¢ÉäÅàÃÀÇúÈûÖÎÁÆÄÔÄ¤×ªÒÆ·ÇСϸ°û·Î°©»¼Õß»ñµÃÓÀÉúÑÄ

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-66

×÷Õߣº´óÁ¬Ò½¿Æ´óѧÁ¥ÊôµÚ¶þÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬´÷Ôçϼ

 

13.Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases

°¢ÃÀÌæÄá165mg¸ß¼ÁÁ¿¶ÔEGFRÍ»±ä·ÇСϸ°û·Î°©»¼ÕßÄÔ×ªÒÆ¾Ö²¿Ï£Íûºó³¤ÆÚÓ¦´ð

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-68

×÷Õߣº°²»ÕÒ½¿Æ´óѧµÚÒ»Á¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬×£ÇåÇå


Ñо¿Éè¼Æ£º8ƪ

1.Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT)

°¢ÃÀÌæÄḨÖúÖÎÁÆ¿ÉÇгýµÄIÆÚº¬¸ß¼¶±ð½á¹¹EGFRÃô¸ÐÍ»±äµÄ·ÇСϸ°û·Î°©µÄÁÆÐ§ºÍÇå¾²ÐÔÁÙ´²Ñо¿

ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP1.27-09

×÷ÕߣºÉϺ£ÊÐÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬º«±¦»Ý¡¢·½ÎÄÌÎ/ÉϺ£ÊзοÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬³ÂêÆ

 

2.Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

°¢ÃÀÌæÄáÍŽáÇÊÄÚ»¯ÁÆÖÎÁÆEGFRÍ»±ä·ÇСϸ°û·Î°©°éÄÔÄ¤×ªÒÆ»¼Õß¼°cfDNA¶¯Ì¬×ª±ä¶ÔÁÆÐ§ºÍÔ¤ºóµÄÕ¹Íû¼ÛÖµ

ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-16

×÷ÕߣºÖØÇì´óѧÁ¥ÊôÈýϿҽԺ£¬£¬£¬£¬£¬£¬£¬£¬Íõΰ

 

3.Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy

°¢ÃÀÌæÄáÍŽῨÂíÎ÷ƽÔÚÅàÃÀÇúÈûÇÊÄÚ×¢ÉäÖÎÁÆEGFRÍ»±äÐͷΰ©ÄÔÄ¤×ªÒÆ°©»¼ÕßÖ¢×´ÐÔñ²ðïÖеÄÁÆÐ§ÆÊÎö

ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-42

×÷Õߣº¹þ¶û±õÒ½¿Æ´óѧÁ¥ÊôµÚ¶þÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÀîÀï

 

4.Efficacy and safety of adjuvant aumolertinib in stage IB-IIIA NSCLC after R0 resection and the correlation between efficacy and postoperative MRD status

°¢ÃÀÌæÄáÊõºó¸¨ÖúÖÎÁÆR0ÇгýµÄIB-IIIAÆÚ·ÇСϸ°û·Î°©»¼ÕßµÄÁÆÐ§ºÍÇå¾²ÐÔ¼°ÊõºóMRDÓëÁÆÐ§Ïà¹ØÐÔµÄÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP07.05-10

×÷Õߣº·ðɽÊеÚÒ»ÈËÃñÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÑîʤÀû

 

5.Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äÑôÐÔNSCLCÄÍÒ©·Ö×Ó±ê¼ÇÎïµÄÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-29

×÷ÕߣºÖйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬¶Î½¨´º

 

6.The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess

°¢ÃÀÌæÄáÍŽáHFSRTÖÎÁÆEGFRÍ»±äNSCLC¶à·¢ÄÔ×ªÒÆ»¼ÕßµÄ×î¼Ñ¸ÉԤʱ»úµÄÁÙ´²Ñо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-40

×÷ÕߣºÉ½¶«Ê¡Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÉÛÙ»

 

7.Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy

°¢ÃÀÌæÄáÓÃÓÚÒ»/¶þ´úTKIÖÎÁƺó¸Î¹¦Ð§Òì³ £» £»£»£»£»£»òδ¾­ÖÎÁƺϲ¢»ù´¡ÐԸβ¡µÄEGFRÍ»±äNSCLCµÄÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-73

×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÂÞ·æ

 

8.Real-world Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area

°¢ÃÀÌæÄáÖÎÁÆEGFRÓÐÊýÍ»±äÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßµÄÕæÊµÌìÏÂÑо¿

ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-77

×÷ÕߣºÀ¥Ã÷Ò½¿Æ´óѧµÚÒ»Á¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÕŽ£Çà

 

Äú¿ÉµÇ¼ÒÔÏÂÍøÖ·£¬£¬£¬£¬£¬£¬£¬£¬Éó²é°¢ÃÀÌæÄá2023 WCLCÈëѡժҪÎÊÌâµÄÏêϸÐÅÏ¢£º

https://cattendee.abstractsonline.com/meeting/10925view=appendToCards&initialSearchId=3&searchId=3

ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿